|1.52 0.07 (4.83%)||12-01 15:59|
|Targets||6-month :||1.95||1-year :||2.25|
|Resists||First :||1.67||Second :||1.92|
|Supports||First :||1.25||Second :||1.03|
|MAs||MA(5) :||1.45||MA(20) :||1.53|
|MA(100) :||1.6||MA(250) :||1.24|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||17||D(3) :||13.7|
|52-week||High :||2.52||Low :||0.55|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BLRX ] has closed above bottom band by 43.4%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||1.48 - 1.49||1.49 - 1.5|
|Low:||1.35 - 1.36||1.36 - 1.37|
|Close:||1.44 - 1.45||1.45 - 1.46|
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||72 (M)|
|Shares Float||874 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||5.2 (%)|
|Shares Short||491 (K)|
|Shares Short P.Month||2,560 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-36.8 %|
|Return on Equity (ttm)||-152.9 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-33 (M)|
|Levered Free Cash Flow||-23 (M)|
|Price to Book value||151|
|Price to Sales||0|
|Price to Cash Flow||-3.28|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|